Sunday, December 5

RNA vaccines are the ones of choice for booster shots against the coronavirus


Spanish experts propose using Pfizer or Moderna for the extra dose after immunization with Janssen. While the US gives the green light to the mixed pattern.

Vials of Moderna, Johnson & Johnson and Pfizer-BioNTech.
Vials of Moderna, Johnson & Johnson and Pfizer-BioNTech.Given RuvicREUTERS
  • Direct latest news on coronavirus
  • Health Who will receive the third dose, when and with what vaccine against the coronavirus

A few months ago, Carolina Darias, head of Health, ruled that “the heterologous Covid-19 vaccination pattern has come to stay.” So the evidence was not current and it was justified by a Spanish study Combivacs, which raised doubts among Spanish researchers and clinicians.

With time, Science has been able to collect more data and now the time has come to analyze it and see what conclusions can be drawn. From the US, the American Drug Agency (FDA) and the Centers for Disease Control and Prevention (CDC) have concluded that a booster dose of Moderna’s Covid-19 vaccines can be administered and Johnson & Johnson (Janssen) for some cases, as was the case with Pfizer previously.

In the case of Moderna, as in Pfizer, the booster dose was approved to be administered six months after receiving the second for those over 65 years of age, as well as for people with immunosuppressive diseases or who live or work in risky places. Secondly, all people who received the single dose of Johnson & Johnson are now eligible for a two-month booster after the first puncture.

Mixed pattern, also in the US

The novelty is that CDC Director Rochelle Walensky, last Thursday, he went beyond the team’s recommendations and openly promoted that people can mix vaccines. “The people can choose which vaccine to receive as a booster dose. Some people may have a preference for the type of vaccine they originally received and others may prefer to receive a different booster, “said Walensky.” CDC recommendations now allow this type of combination, “added the CDC director.

For its part, the FDA also took this step the day before, on Wednesday. The US agency approved the use of a different Covid vaccine for the booster dose than that originally used for immunization, it said in a statement. “The FDA has determined that the known and potential benefits of using a single booster dose distinct outweigh the known and potential risks of their use in eligible populations. “

Now, in the US, a single dose of any of them can be used as a booster of the primary vaccination, even if it is from a different laboratory than the vaccination received initially. According to the new decision, people who received two of Moderna initially and are 65 or older, those over 18 at high risk, and with high exposure for their work, can now receive an ‘extra’.

Pfizer and Moderna for the second Janssen puncture in Spain

Thus, in Spain this decision can see the light next week. Yesterday, the Presentation of Vaccines, made up of experts, is going to propose to the Public Health Commission that inject a booster dose of Pfizer or Moderna to the nearly two million people who received the Janssen single-dose serum. As sources close to the presentation have confirmed to this newspaper, this booster dose represents a possibility that vaccine experts have considered for a long time since the same laboratory, at the time it applied its only vaccine, launched a clinical trial to the second dose for what it supposes of improvement in the effectiveness.

Once transferred to the Public Health Commission, the proposal must be approved by the Interterritorial Council of the Public Health System (CISNS), made up of the Ministry of Health and the autonomous communities. This could be next Wednesday, in the fortnightly appointment of the autonomous plenary session.

Up to now, mRNA-based vaccines are chosen for extra and extra doses. In the ninth update of the Health Strategy these new ’rounds’ of immunization are already being collected. These mechanisms have already been approved by the Interterritorial for people over 70 years of age and groups at high risk due to low immunity, and those receiving treatment with immunosuppressive drugs, and the rest of the population. risk groups included in group 7 of the strategy. They have also been administered booster doses to institutionalized people in senior centers.

According to the criteria of

The Trust Project

Know more

Leave a Reply

Your email address will not be published. Required fields are marked *